Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medroxyprogesterone acetate versus GnRH antagonist in oocyte donors
2017-002341-30Phase 3Completed
- Sponsor
- IVI
- Start
- Jun 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of medroxyprogesterone acetate in Premature luteinization (PL) (2 arms), sponsored by IVI. Primary endpoints: Number of oocytes, Number of metaphase II oocytes (MII) and 1 more. Started Jun 2017; status: completed.
02
Drugs
medroxyprogesterone acetate
03
Conditions
Premature luteinization (PL)
Beyond the preview
Go deeper on 2017-002341-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002341-30.